These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11378378)

  • 61. Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
    Dai Y; Guo Y; Guo J; Pease LJ; Li J; Marcotte PA; Glaser KB; Tapang P; Albert DH; Richardson PL; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1897-901. PubMed ID: 12749893
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
    Bieliauskas AV; Weerasinghe SV; Pflum MK
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2216-9. PubMed ID: 17307359
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MMP inhibition and the development of cerebrovascular atherosclerosis: The road ahead.
    Napoli C
    Stroke; 2002 Dec; 33(12):2864-5. PubMed ID: 12494909
    [No Abstract]   [Full Text] [Related]  

  • 64. Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives.
    Nagaoka Y; Maeda T; Kawai Y; Nakashima D; Oikawa T; Shimoke K; Ikeuchi T; Kuwajima H; Uesato S
    Eur J Med Chem; 2006 Jun; 41(6):697-708. PubMed ID: 16584813
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid.
    Kahnberg P; Lucke AJ; Glenn MP; Boyle GM; Tyndall JD; Parsons PG; Fairlie DP
    J Med Chem; 2006 Dec; 49(26):7611-22. PubMed ID: 17181145
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.
    Barta TE; Becker DP; Bedell LJ; Easton AM; Hockerman SL; Kiefer J; Munie GE; Mathis KJ; Li MH; Rico JG; Villamil CI; Williams JM
    Bioorg Med Chem Lett; 2011 May; 21(10):2820-2. PubMed ID: 21507637
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 68. Solid-phase synthesis of di- and tripeptidic hydroxamic acids as inhibitors of procollagen C-proteinase.
    Dankwardt SM; Billedeau RJ; Lawley LK; Abbot SC; Martin RL; Chan CS; Van Wart HE; Walker KA
    Bioorg Med Chem Lett; 2000 Nov; 10(22):2513-6. PubMed ID: 11086718
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
    Tessier P; Smil DV; Wahhab A; Leit S; Rahil J; Li Z; Déziel R; Besterman JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5684-8. PubMed ID: 19699639
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Solid-phase synthesis of alpha-substituted 3-bisarylthio N-hydroxy propionamides as specific MMP inhibitors.
    Chollet AM; Le Diguarher T; Kucharczyk N; Loynel A; Bertrand M; Tucker G; Guilbaud N; Burbridge M; Pastoureau P; Fradin A; Sabatini M; Fauchère JL; Casara P
    Bioorg Med Chem; 2002 Mar; 10(3):531-44. PubMed ID: 11814839
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.
    Levin JI; Du MT; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Moy FJ; Powers R; Jin G; Cowling R; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):235-8. PubMed ID: 11206467
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synthesis and antimetastatic activity of 6-trichloroacetamido and 6-guanidino analogues of siastatin B.
    Satoh T; Nishimura Y; Kondo S; Takeuchi T; Azetaka M; Fukuyasu H; Iizuka Y; Ohuchi S; Shibahara S
    J Antibiot (Tokyo); 1996 Mar; 49(3):321-5. PubMed ID: 8626252
    [No Abstract]   [Full Text] [Related]  

  • 74. A novel series of highly selective inhibitors of MMP-3.
    Whitlock GA; Dack KN; Dickinson RP; Lewis ML
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
    Hanessian S; Bouzbouz S; Boudon A; Tucker GC; Peyroulan D
    Bioorg Med Chem Lett; 1999 Jun; 9(12):1691-6. PubMed ID: 10397503
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity.
    Zhang H; Wang X; Mao J; Huang Y; Xu W; Duan Y; Zhang J
    Bioorg Med Chem; 2018 Aug; 26(15):4363-4374. PubMed ID: 30093347
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model.
    Nasu Y; Nishida K; Miyazawa S; Komiyama T; Kadota Y; Abe N; Yoshida A; Hirohata S; Ohtsuka A; Ozaki T
    Osteoarthritis Cartilage; 2008 Jun; 16(6):723-32. PubMed ID: 18226559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.